Data Insights
                                    By  Company Name
                                
                                No Filter Selected
                                    By  Disease Name
                                
                                No Filter Selected
                                    By  Drug Name
                                
                                No Filter Selected
                                    By Themes
                                
                                No Filter Selected
                                    Showing 1 results out of 1                                
                                
                                                Data Insights
                                                
                                        ASC-60 by Sagimet Biosciences for Solid Tumor: Likelihood of Approval
ASC-60 is under clinical development by Sagimet Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...